|
|
 Previous Article | Table of Contents | Next Article 
Pharmacokinetics and effects of recombinant human erythropoietin after
intravenous and subcutaneous injections in healthy volunteers
FG McMahon, R Vargas, M Ryan, AK Jain, RI Abels, B Perry and IL Smith
Clinical Research Center, New Orleans, LA 70112.
A double-blind, placebo-controlled study of the pharmacokinetics and safety
of multiple doses of recombinant human erythropoietin [rHuEPO 150 or 300
U/kg either by intravenous (IV) bolus or subcutaneously (SC)] in normal
male subjects demonstrated that rHuEPO had a dose- related effect on the
hematocrit independent of the route of administration and that multiple
doses of rHuEPO had no direct pressor effects. When rHuEPO was injected IV,
a monoexponential decrease in serum EPO level was evident for 18 to 24
hours postdose. Absorption of SC injected rHuEPO occurred more slowly, with
relatively low serum EPO levels being maintained for 48 hours. All rHuEPO
antibody titer determinations were negative. With the exception of
significant increases in hemoglobin and hematocrit, no clinically
significant changes occurred. No hypertensive, convulsive, or thrombotic
events were observed. Of the adverse experiences observed in 10 subjects,
none was considered clinically significant, and none of the subjects
dropped out because of adverse experiences.
Volume 76,
Issue 9,
pp. 1718-1722,
11/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Burger, F. Xiang, L. Hammoud, X. Lu, and Q. Feng
Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion
Am J Physiol Heart Circ Physiol,
January 1, 2009;
296(1):
H84 - H93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bouman-Thio, K. Franson, B. Miller, J. Getsy, A. Cohen, S. A. Bai, J. Yohrling, B. Frederick, S. Marciniak, Q. Jiao, et al.
A Phase I, Single and Fractionated, Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects
J. Clin. Pharmacol.,
October 1, 2008;
48(10):
1197 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Stead, J. Lambert, D. Wessels, J. S. Iwashita, K. K. Leuther, K. W. Woodburn, P. J. Schatz, D. M. Okamoto, R. Naso, and A.-M. Duliege
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers
Blood,
September 15, 2006;
108(6):
1830 - 1834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ramakrishnan, W. K. Cheung, M. C. Wacholtz, N. Minton, and W. J. Jusko
Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers
J. Clin. Pharmacol.,
September 1, 2004;
44(9):
991 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Johnson, C. Chebli, and A. J. Aboulafia
Epoetin Alfa
J. Am. Acad. Ortho. Surg.,
March 1, 2003;
11(2):
77 - 80.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Coladonato, D. L. Frankenfield, D. N. Reddan, P. S. Klassen, L. A. Szczech, C. A. Johnson, and W. F. Owen Jr.
Trends in Anemia Management among US Hemodialysis Patients
J. Am. Soc. Nephrol.,
May 1, 2002;
13(5):
1288 - 1295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Piron, M. Loo, A. Gothot, F. Tassin, G. Fillet, and Y. Beguin
Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia
Blood,
January 15, 2001;
97(2):
442 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Kaufman, D. J. Reda, C. L. Fye, D. S. Goldfarb, W. G. Henderson, J. G. Kleinman, C. A. Vaamonde, and The Department of Veterans Affairs Cooperative Stu
Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis
N. Engl. J. Med.,
August 27, 1998;
339(9):
578 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Sytkowski, E. D. Lunn, K. L. Davis, L. Feldman, and S. Siekman
Human erythropoietin dimers with markedly enhanced in vivo activity
PNAS,
February 3, 1998;
95(3):
1184 - 1188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kato, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama
Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats
J. Pharmacol. Exp. Ther.,
November 1, 1997;
283(2):
520 - 527.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Cazzola, F. Mercuriali, and C. Brugnara
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
Blood,
June 15, 1997;
89(12):
4248 - 4267.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Goodnough, T. G. Monk, and G. L. Andriole
Erythropoietin Therapy
N. Engl. J. Med.,
March 27, 1997;
336(13):
933 - 938.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sowade, H. Warnke, P. Scigalla, B. Sowade, W. Franke, D. Messinger, and J. Gross
Avoidance of Allogeneic Blood Transfusions by Treatment With Epoetin Beta (Recombinant Human Erythropoietin) in Patients Undergoing Open-Heart Surgery
Blood,
January 15, 1997;
89(2):
411 - 418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
